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Abstract
Background: The increasing risk of obesity and diabetes among other metabolic disorders are the consequence of
shifts in dietary patterns with high caloric-content food intake. We previously reported that megalin regulates
energy homeostasis using blood-brain barrier (BBB) endothelial megalin-deficient (EMD) mice, since these animals
developed obesity and metabolic syndrome upon normal chow diet administration. Obesity in mid-life appears to
be related to greater dementia risk and represents an increasing global health issue. We demonstrated that EMD
phenotype induced impaired learning ability and recognition memory, neurodegeneration, neuroinflammation,
reduced neurogenesis, and mitochondrial deregulation associated with higher mitochondrial mass in cortical tissues.
Methods: EMD mice were subjected to normal chow and high-fat diet (HFD) for 14 weeks and metabolic changes
were evaluated.
Results: Surprisingly, BBB megalin deficiency protected against HFD-induced obesity improving glucose tolerance and
preventing hepatic steatosis. Compared to wild type (wt), the brain cortex in EMD mice showed increased levels of the
mitochondrial biogenesis regulator, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), and
uncoupling protein 2 (UCP2), a thermogenic protein involved in the regulation of energy metabolism. This
agreed with the previously found increased mitochondrial mass in the transgenic mice. Upon HFD challenge,
we demonstrated these two proteins were found elevated in wt mice but reported no changes over the
already increased levels in EMD animals.
Conclusion: We propose a protective role for megalin on diet-induce obesity, suggesting this could be
related to metabolic disturbances found in dementia through brain endocrine system communications.
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Background
Urban lifestyle conducts changes in human eating habits,
in which intake of high caloric content foods come along
with reduced physical activity. This context is putatively
associated with many epidemic chronic diseases that
have emerged in relatively recent times. For example,
obesity has been found to increase in developed coun-
tries where high-calorie food intake is a major cause of
this global health problem. Food intake and energy ex-
penditure balance modulate body weight, and this is reg-
ulated mainly through hormone leptin [1]. Leptin is
internalized by the multiligand endocytic receptor mega-
lin, also known as low-density lipoprotein receptor-
related protein 2 (LRP-2) or glycoprotein 330, the largest
member of the low-density lipoprotein receptor (LDLR)
family [2, 3]. Megalin is expressed in several absorptive
epithelial cells, and in the central nervous system (CNS)
mainly in the blood-brain barrier (BBB). Because mega-
lin binds and internalizes leptin and insulin [4–6], and
megalin is expressed exclusively in brain endothelial
cells, we previously set out to specifically delete the
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endothelial megalin in C57/BL6 mice using the Cre/loxP
system (EMD mice) [7, 8] to explore the metabolic im-
pact of BBB megalin deletion [9]. These EMD mice de-
veloped neurodegeneration and impaired learning and
memory abilities, similar to symptoms described in AD
[9]. Also, we reported this mouse model displayed obes-
ity and metabolic syndrome, mediated by leptin signaling
disruption in the hypothalamus, upon normal chow diet
administration [10]. Hence, we consider this model gives
the opportunity to explore and understand several over-
lapping and common mechanisms, including mitochon-
drial dysfunction, that is observed in these disorders.
Obesity in mid-life appears to be related to greater de-
mentia risk and there are several studies reporting this
connection [11–15]. This is consistent with the observed
higher Alzheimer’s disease (AD) incidence in world re-
gions associated with high risk of obesity, sedentarism,
diabetes, hypertension, dyslipidemia, and metabolic syn-
drome [16, 17]. A number of adverse neuronal effects have
been observed under obese conditions [18]. Higher dietary
fat intake has been associated with increased AD risk [19].
Also, using common AD mouse models, it has been found
diet-induced obesity accelerates AD-related pathology
[20–24]. Paradoxically, it is known that AD subjects show
a hypermetabolic state accompanied by increased energy
expenditure. This makes AD patients undergo a signifi-
cant weight loss even when they have increased food in-
take [25]. These features have been observed still in
patients with the preclinical condition of mild cognitive
impairment (MCI) [26, 27]. In our EMD mouse model, we
firstly demonstrated that BBB megalin deletion induced
impaired learning ability and recognition memory, and
neurodegeneration, similar to symptoms described in AD
[9]. More recently, we also showed these mice displayed
neuroinflammation, reduced neurogenesis and mitochon-
drial deregulation associated with higher mitochondrial
mass in cortical tissues [10].
In the present study, we investigated the effects of HFD
challenge in EMD mice compared to wt animals. We found
that BBB megalin deletion preserved HFD-induced metabolic
alterations and obesity. We consider it important to fully
characterize EMD mice as this model constitutes a valuable
obesity model, linking obesity and neurodegeneration as pre-
viously was already demonstrated that megalin deletion in
brain endothelial cells could be a novel mechanism to pro-
mote neurodegeneration and obesity. Our mice model would
help to understand the molecular mechanisms that may link




Male EMD mice were generated using the Cre/loxP sys-
tem under the control of the Tie2 as previously reported
[10]. Wild-type (wt) littermates (i.e., Tie2-Cre −mice)
were used as controls (megalin flox/flox). EMD and con-
trol mice were housed on a 12 h light/12 h dark schedule.
At the age of 3 weeks, male EMD and WT mice (16–18
per group) were provided a normal chow diet (NCD, 10%
fat in kilocalories) or high-fat diet (HFD) containing 60%
fat (Harlan Teklad, USA) ad libitum for 14 weeks. Body-
weight was monitored weekly throughout the study. At
the end of experiments, animals were anesthetized with
isoflurane, blood was drawn, and perfused transcardially
with saline buffer or 4% paraformaldehyde in 0.1M phos-
phate buffer (PB, pH 7.4) for biochemical and immunohis-
tochemical analysis, respectively. Then, the brain, liver,
and adipose tissue were collected for further processing
and stored at − 80 °C until analysis. The liver and adipose
tissue were previously weighed. Visceral fat was collected
and weighed prior to − 80 °C storage, and average ob-
tained weights per group are shown expressed in grams
(Fig. 1b). All animals were handled and cared for accord-
ing to the Council Directive 2010/63/UE of 22 September
2010 (animal experiment license number: CEI 97–1778–
A291).
Metabolic studies
Glucose tolerance test was assessed prior to sacrifice.
After 14 weeks under the diets, a glucose tolerance test
was performed. Briefly, mice were fasted for 16 h before
receiving intraperitoneal (ip) administration of 2 g/kg
body weight of glucose in saline (0.9% NaCl). Blood
samples of conscious mice were taken from the tail vein
at 0, 15, 30, 60, and 120 min after glucose loading, and
the blood glucose levels were determined. Blood glucose
measurements were performed using a glucometer
(Accu-Chek, Roche, Mannheim, Germany).
The insulin-tolerance test was performed with male mice
after 6 h fast. The animals were ip injected with 0.75 UI/kg
body weight of insulin (Actrapid, Novo Nordisk Pharma,
Bagsvaerd, Denmark). Blood glucose measurements were
performed with the glucometer before the injection and at
15, 30, 60, and 120min after the injection. Serum triglycer-
ides (TG), total cholesterol, HDL cholesterol, non-esterified
fatty acids (NEFA), leptin, and insulin were determined
using commercial kits from Abcam (Abcam, Cambridge,
UK) and Wako Diagnostics, (Richmon, USA).
Immunohistochemistry
Liver tissue was fixed for 24 h in 4% paraformaldehyde
(PFA) by immersion. Then, liver samples were cryopro-
tected overnight in 30% sucrose 0.1M phosphate buffer,
frozen at − 80 °C, and sectioned at 20 μm using a Leica
cryostat (Leica, Wetzlar, Germany). Oil Red O (Sigma-Al-
drich, St. Louis, USA) staining was performed according to
standard procedures and counterstained with hematoxylin-
eosin (H-E, Thermo Fisher Scientific, MA, USA). Briefly,
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liver sections were washed with running tap water for 10
min, rinsed with 60% isopropanol, and stained with Oil Red
O mixed with 60% isopropanol for 15min. The sections
were then rinsed with 60% isopropanol, and nuclei
were stained with H-E, rinsed in tap water, and
mounted in coverslips with aqueous mounting
medium. Images were captured using a light micro-
scope (Zeiss microscope; Carl Zeiss Microimaging,
GmbH, Oberkochen, Germany) at × 40 magnification
from five different fields. Positive areas of Oil Red O
Fig. 1 EMD mice display a significant reduction in HFD-induced obesity phenotype. Wt and EMD male mice were fed with NCD or HFD for 14weeks. a Under
NCD, bodyweight gain during 14-week feeding was significantly increased in EMD mice compared to wt. HFD administration significantly increased body
weight in both mice groups but this increase was much more significant in wt group (n=9, in all animal groups). b Fat weight in NCD-fed or HFD-fed mice at
week 14. c Glucose tolerance test in wt and EMD mice fed with NCD or HFD for 14weeks in the 16-h-fasted state (wt NCD, n=5; wt HFD, n=6; EMD NCD,
n=8; EMD HFD n=9). d Scatter plots with bars represent the area under the glucose curve from the glucose tolerance test. e Insulin tolerance test in wt and
EMD mice fed with NCD or HFD for 14weeks in the 6-h-fasted state (wt NCD, n=5; wt HFD, n=6; EMD NCD, n=8; EMD HFD n=9). f Scatter plots with bars
represent the area under the glucose curve from the insulin tolerance test. All data are presented as the mean± SEM. Statistical significance in a, c and e is
based on multivariate ANOVA analysis followed by Games-Howell post hoc test. Statistical significance in b, d, and f was based on one-way ANOVA followed
by Games-Howell’s (b and d) or Tukey’s (f) post hoc test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
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staining, corresponding to red droplets, were calcu-
lated using a color differentiation system and the re-
sult is expressed as the total area of the image using
Image J software (U. S. National Institutes of Health,
Bethesda, MD, USA).
Western blot analysis
Protein extracts were prepared from frontal cortex cere-
bral tissue by mechanic homogenization in ice-cold lysis
buffer NP-40 (50mM Tris-base pH 7.4, 150mM NaCl,
0.5% Nonidet P-40, 1mM EDTA) containing a mixture of
protease and phosphatase inhibitors (Roche Applied Sci-
ence, Basel, Switzerland) and centrifuged for 15min at
14000 rpm at 4 °C. Supernatants were collected, and the
total protein concentrations were estimated by BCA assay
(Pierce BCA Protein Assay Kit, Thermo Fisher, Waltham,
MA, USA). Twenty micrograms from each sample were
loaded in a precast 4–20% Tris-Glycine gels (Thermo
Fisher Scientific, MA, USA) and transferred to polyvinyli-
dene fluoride (PVDF) membranes (Bio-Rad, CA, USA).
Then, membranes were blocked and incubated with the
corresponding primary antibody: mouse monoclonal anti-
Glial fibrillary acidic protein (GFAP, 1:2500; Sigma-
Aldrich, G3893; St. Louis, USA); rabbit polyclonal anti-
Ionized calcium-binding adaptor molecule 1 (Iba1, 1:1000;
Wako Diagnostics, 016–20,001; Richmond, USA), mouse
monoclonal anti-complex V β subunit (CxVβ) (1:1000;
Abcam, ab14730; Cambridge, UK), rabbit polyclonal anti-
peroxisome proliferator-activated receptor γ co-activator
1α (PGC-1α; 1:200; Santa Cruz Biotechnologies, sc13067;
CA, USA), rabbit polyclonal anti-UCP-2 (1:1000; Abcam,
ab203244; Cambridge, UK) and mouse monoclonal anti-
β-actin (1:40000, Abcam ab49900, Cambridge, UK) to
monitor protein loading control. Secondary horseradish
peroxidase-conjugated goat anti-mouse (1:5000; Bio-Rad,
170–6516; CA, USA) and goat anti-rabbit (1:5000;
Thermo Fisher Scientific, A16110; MA, USA) were used.
Immunoreactive bands were detected using an enhanced
chemiluminescence reagent (ECL Clarity, Bio-Rad, CA,
USA) using the ImageQuant TL Image Analysis system
version 7.0 (LAS 4000, GE Healthcare, Chicago, IL, USA).
Densitometric quantification was carried out with Image
Studio Lite 5.0 software (Li-COR Biosciences, NE, USA).
Protein bands were normalized to β-actin levels and
expressed as a percentage of the control group.
Data analysis
Immunohistochemistry images were minimally proc-
essed in a uniform matter across treatment groups and
were analyzed using ImageJ software (NIH, Bethesda,
MD, USA). Results are presented in scatter plots with
bars. Statistical analysis was carried out using GraphPad
Prism 6.01 software (La Jolla, CA, USA) and IBM SPSS
Statistics Version 21.0. (Armonk, NY, USA). Grubbs
outlier filter was used for all data and the Shapiro-Wilk
normality test was carried out to check normality. When
results met normality criteria one-way ANOVA and
Levene’s test to analyze homoscedasticity were per-
formed in order to choose suitable post hoc analysis
(Tukey’s or Games-Howell’s tests) to determine individ-
ual differences. When results did not meet normality cri-
teria Kruskal-Wallis ANOVA was used. For experiments
showing weight and glucose curves over time with all
different conditions, a mixed ANOVA analysis was car-
ried out and sphericity was checked with Mauchly’s test.
When sphericity was violated (weight and glucose re-
sults), a multivariate ANOVA analysis was conducted.
When results did not meet homogeneity criteria, the
Games-Howell post hoc test was carried out. A p value
equal to 0.05 or less was considered statistically
significant.
Results
BBB megalin deletion protects to HFD-induced obesity
Megalin deletion in brain endothelial cells was previ-
ously shown to be a novel mechanism promoting obesity
[10]. Additionally, it is known that brain megalin dele-
tion activates obesity-induced neuropathological mecha-
nisms similar to those found in AD models [9, 10]. On
the grounds of the observed hypermetabolic state and
weight loss in AD patients even when they are under
HFD intake, we wondered how HFD challenge could
affect BBB megalin deletion mouse model weight and
glucose metabolism. To address this question, EMD and
wt animals were fed with HFD and NCD for 4months.
Figure 1a shows weight gain in the grouped animals dur-
ing this time. EMD mice fed with NCD exhibited higher
weight gain compared to wt animals (Fig. 1a), equivalent
to the previously reported results [10]. HFD administra-
tion induced a significant weight gain in both wt and
EMD mice, but such an increase was much more repre-
sentative in wt group (Fig. 1a). Although fat weight was
increased in both wt and EMD mice groups 14 weeks
after HFD diet administration (Fig. 1b), only wt mice
showed significant fat weight gain compared to those
mice fed with NCD (P < 0.01; Fig. 1b). The increase in
fat mass in EMD mice was found 28.6% lower than that
observed in wt mice (Fig. 1b). These results suggest that
EMD deficiency may protect against diet-induced
adiposity.
We next investigated whether fat mass gains in mice
under HFD challenge would lead to improved glucose
handling and insulin sensitivity. Indeed, glucose tolerance
test 14 weeks after HFD administration revealed a signifi-
cant protection to glucose intolerance in EMD mice com-
pared to wt group (Fig. 1c) as HFD administration did not
change the resulting area under the glucose curve (AUC-
GTT) in EMD mice as occurred in wt mice (P < 0.05;
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Fig. 1d). Similar glucose disposal rates upon insulin ad-
ministration were found between groups (Fig. 1e, f). To-
gether, these results indicate BBB megalin deletion may
exert a protective effect on the HFD-induced obesity
phenotype.
HFD-induced lipid dyshomeostasis is attenuated in EMD
mice
Lipid homeostasis in serum was also evaluated. HFD admin-
istration resulted in increased serum triglyceride levels in
both, wt (P < 0.0001; Fig. 2a) and EMD (P < 0.05; Fig. 2a)
mice compared to mice fed with NCD. However, whereas
high-density lipoprotein (HDL) levels in wt mice were found
increased upon HFD administration compared to NCD-fed
animals (P < 0.001; Fig. 2b), no effect on these levels was
found in HFD-fed EMD mice. (Fig. 2b). Surprisingly, serum
cholesterol levels remained unchanged in EMD mice com-
pared to wt mice under NCD and as well as upon HFD ad-
ministration (Fig. 2c). No differences were found in non-
esterified fatty acid (NEFA) among the genotypes and diets
(Fig. 2d).
Leptin and insulin levels in serum were found higher in
EMD mice compared to wt mice upon NCD administration
according to previous data (Leptin = P < 0.05; Fig. 2e; Insu-
lin = P < 0.05; Fig. 2f). After 14weeks of HFD, wt mice dis-
played a significant increase in serum leptin levels (P < 0.01;
Fig. 2 Serum metabolic parameters in wt and EMD mice under NCD and HFD for 14 weeks. (a–f) a Triglycerides (TG), b high-density lipoprotein
(HDL), c cholesterol, d non-esterified fatty acid (NEFA), e leptin, and f insulin tests in wt and EMD mice fed with NCD or HFD for 14 weeks. All
data are presented as the mean ± SEM. Statistical significance was based on one-way ANOVA followed by Games-Howell’s (a, c, d, and f) or Tukey’s
(b and e) post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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Fig. 2e), whereas HFD challenge did not change serum leptin
levels in EMD mice (Fig. 2e). Serum insulin levels were also
found increased in wt upon HFD (P < 0.01; Fig. 2f) but in
EMD group, insulin levels remained unchanged after 14
weeks HFD feeding (Fig. 2f).
EMD mice display reduced liver damage upon HFD
administration
Linked to lipid homeostasis is the liver health and lipid dys-
homeostasis induce liver lipid accumulation. Therefore, we
next analyzed lipid accumulation in mice liver sections from
HFD-fed mice compared to mice fed with NCD. H&E and
Oil Red O-co-staining showed an increased number of red
droplets in wt but not in EMD mice upon HFD challenge in-
dicating liver lipid accumulation and hepatic steatosis
(Fig. 3a). Oil Red O histological analysis of liver sections
showed a significant increase of lipid infiltration in HFD-fed
wt mice compared to NCD-fed animals (P < 0.01; Fig. 3b). In
addition, after 14weeks of HFD feeding, EMD mice exhib-
ited a significant reduction in liver weight (P < 0.05) not ob-
served in wt mice (Fig. 3c).
HFD challenge does not affect the PGC1-1α and UCP2
brain cortex levels in EMD mice
We previously demonstrated that mitochondrial mass
was increased in brains from EMD mice compared to wt
animals [10]. It is known that HFD induces an increase
in mitochondrial mass [28]; therefore, we wondered how
HFD administration could affect mitochondrial mass
levels in the frontal cerebral cortex of EMD mice. To
this end, we estimated the amount of total mitochondrial
mass in this brain area by analyzing the levels of the
structural mitochondrial protein complex V, β subunit
(CxVβ) by immunoblotting (Fig. 4a). The mitochondrial
mass analysis confirmed the previously reported results
showing that upon NCD administration, brain cortical
samples from EMD mice displayed significant elevated
mitochondrial mass levels compared to wt animals (P <
0.01; Fig. 4a,). Upon HFD administration, mitochondrial
mass levels remained unchanged. Then, we analyzed
PGC-1α levels as this protein is the master regulator of
mitochondrial biogenesis in order to verify whether
these protein levels could be related to the observed
changes in mitochondrial mass upon HFD administra-
tion. PGC-1α was found significantly increased in EMD
mice frontal cerebral cortex samples compared to sam-
ples from the same brain area in wt animals (P < 0.01;
Fig. 4b). HFD administration induced an increase in
PGC-1α protein levels in wt mice compared with ani-
mals from the same group fed with NCD (P < 0.05;
Fig. 4b). However, the HFD challenge did not alter PGC-
1α protein levels on EMD mice (Fig. 4b). Apart from the
mitochondrial biogenesis, PGC-1α regulates uncoupling
protein-2 (UCP2), a thermogenic protein involved in the
regulation of energy metabolism. EMD mice fed with
NCD showed increased UCP2 levels compared to wt
mice in agreement with the highly observed PGC-1α
levels (P < 0.05; Fig. 4c). HFD administration to wt mice
reported an increase in UCP2 levels (P < 0.05; Fig. 4c)
reaching similar values to those observed in NCD
treated EMD mice. No differences in UCP2 levels were
Fig. 3 EMD mice are protected against HFD-induced hepatic
steatosis. a Representative images of Oil Red O and H&E co-stained
liver sections from NCD and HFD-fed wt and EMD mice. Arrows
indicate lipidic stained droplets. Scale bar: 50 μm. b Scatter plots
with bars showing the quantification of intracellular fat drops
followed by Oil Red O staining. c Liver weight in NCD or HFD-fed
mice at week 20. All data are presented as the mean ± SEM.
Statistical significance was based on one-way ANOVA followed by
Games-Howell’s post hoc test. *P < 0.05, **P < 0.01
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observed in EMD mice, indicating this pathway could be
already activated (Fig. 4c).
HFD challenge does not affect glial activation in EMD mice
It is known that diet-induced obesity triggers glial activa-
tion. A recent study reported a link between
mitochondrial dynamics and inflammation, showing that
HFD induced an increase in UCP2 expression that medi-
ates neuroinflammation [29]. We then tested astrocyte
and microglial inflammatory markers in frontal cerebral
cortex from wt and EMD mice upon HFD challenge.
Consistent with our previous work [10], we found
Fig. 4 HFD challenge does not affect the PGC1-1α and UCP2 cortex levels in EMD mice. (a–c) a Protein levels of Complex V-β subunit (CxVβ),
b PGC-1α, and c UCP-2 were significantly higher in EMD mice cortical samples compared to samples from the same brain area in wt animals
under NCD. HFD administration increased b PGC-1α, and c UCP-2 protein levels in wt mice but not in EMD mice. Scatter plots with bars
represent the quantification of protein expression in each animal group, and representative western blots are shown (right panels). All data
represent the mean of at least 3 independent experiments ±SEM. Statistical significance was based on the Kruskal-Wallis ANOVA test (a) or
one-way ANOVA (b and c) followed by Games-Howell’s post hoc test (b and c). *P < 0.05, **P < 0.01
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significant higher GFAP levels, in the cerebral cortex of
NCD-fed EMD mice compared to wt mice (P < 0.05;
Fig. 5a, c) indicating astrogliosis. Upon HFD administra-
tion we also found significantly increased GFAP levels in
the cerebral cortex of wt mice, compared to NCD-fed
animals (P < 0.05; Fig. 5a, c) but no changes upon HFD
administration were found in EMD mice. The analysis of
Iba-1 levels did not report significant differences be-
tween mice groups (Fig. 5b, c) although a trend of in-
creased levels was found upon HFD administration in
both of them.
Discussion
Endocytic multiligand receptor megalin internalizes lep-
tin, a hormone modulator of body weight through the
balance of food intake and energy expenditure [1]. Here,
we show that the HFD-induced obesity phenotype is at-
tenuated in EMD mice compared to wt-fed animals. We
found that HFD-fed EMD mice developed reduced body
weight gain and improved glucose tolerance. About fat
body composition, several interesting observations were
observed. High fat diet-fed wt mice demonstrated hyper-
insulinemia and hyperleptinemia as well as elevated cir-
culating triglyceride levels, and hepatic steatosis in
comparison with control diet-fed mice, consistent with
previous studies [30]. However, over the 14 weeks HFD-
treatment period, EMD mice exhibited less overweight,
and fat gain compared with wt mice, and contrary to ex-
pected, leptin and insulin levels did not change. Also,
HFD-fed EMD mice did not show hepatic steatosis. Up-
regulation of PGC-1α and thermogenic protein UCP2
was observed in the brain cortex from HFD-fed wt mice.
Such increases were not apparent in EMD mice as both
PGC-1α and UCP2 levels were found already increased
with normal chow diet. This result is consistent with the
previously reported increased mitochondrial mass de-
tected in EMD mice compared to wt as PGC-1α is a
master regulator of mitochondrial biogenesis. Our re-
sults suggest BBB endothelial megalin deletion protects
HFD-induced obesity in mice, insulin resistance and
hepatic steatosis through brain endocrine system
communications.
Our present study agrees with previous findings that
identify LRP-6 as bodyweight and glucose metabolism
regulator [31]. In that study, authors reported that
LRP6+/− mice on high-fat diet are protected against diet-
induced obesity. We previously demonstrated that the
silencing of megalin in the mouse brain endothelium
was sufficient to increase the weight gain and adiposity
triggering hyperleptinemia, hyperinsulinemia, increased
triglyceride blood levels, and impaired glucose tolerance
[10]. Additionally, we provided evidences supporting
megalin as physiological energy balance regulator in
agreement with other works [32–34].
Megalin knockout mice manifest abnormalities in the
development of brain and other tissues, including lung
and kidney [35]. This phenotype is consistent with a role
of megalin as endocytic receptor that mediates the cellu-
lar uptake of essential nutrients, possibly lipoproteins-
Fig. 5 Glial activation markers in wt and EMD mice under NCD and
HFD for 14 weeks. (a–c) a Protein levels of GFAP, and b Iba1 were
significantly higher in HFD-fed wt mice compared to NCD fed
animals. Upon NCD, GFAP expression was also significantly increased
in EMD mice compared to wt mice. a, b Scatter plots with bars
represent protein levels quantification in each animal group. c
Representative western blots are shown. All data are presented as
the mean ± SEM. Statistical significance was based on one-way
ANOVA test followed by Games-Howell’s post hoc test (b and
c). *P < 0.05
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derived cholesterol. A series of preceding biochemical
and experimental studies have provided compelling evi-
dence showing that megalin plays an important role in
modulating protein and lipids transport [4]. Indeed, sev-
eral studies revealed that megalin can also act as a recep-
tor to transport leptin in the renal epithelium [6, 36].
Additionally, in a previous work, we showed that leptin
entry into the brain occurs through its binding to mega-
lin and the effects of blocking megalin expression indi-
cated that leptin needs megalin to exert its function in
the brain [5]. Then, food intake regulation and subse-
quent energy balance depend on the efficiency of leptin
delivery in CNS [37]. There are not consistent results
regarding the effects of high-fat diet administration com-
pared to standard diets on triglyceride levels. Guo et al.
showed mice fed for 7 weeks with obesogenic diets (60%
high fat diet enriched) exhibited lower serum triglyceride
levels compared with normal chow diet [38]. Contrarily,
in a previous work, we demonstrated western-style high
fat diet in rats fed during 1 and 3 months increased lipid
profile levels including triglycerides and HDL compared
to rats fed with a standard diet [39]. We confirm here
the obesity phenotype in EMD mice as they show in-
creased triglyceride levels along with hyperleptinemia
and hyperinsulinemia. We did not find changes in NEFA
levels between groups and diets.
Although cholesterol levels between EMD mice and wt
were not found different, other blood metabolic parame-
ters showed typical obese phenotype as increased trigly-
ceride levels, increased insulin and increased leptin
levels. Surprisingly, increased HDL levels were also
found to increase in EMD mice compared to wt. This
may account for undetectable differences in cholesterol
levels between EMD and wt mice. Upon HFD adminis-
tration wt mice showed increased blood levels of triglyc-
erides, insulin and leptin, and also HDL, while EMD
mice only showed enhanced triglyceride levels but did
not show changes in the already increased insulin, leptin,
and HDL blood levels. Since megalin mediates HDL
endocytosis [40], the lack of this receptor in EMD mice
may impair HDL brain uptake resulting in the observed
high circulating HDL levels, regardless of feeding. Our
results here agree with those from Dietrich et al., as we
found wt mice exhibited increased triglyceride and HDL
levels after HFD administration. As was demonstrated in
previous works, we may speculate such controversy
comes from the timing of HFD feeding, animal strain
and/or diet composition [41, 42]. Under NCD, EMD
mice showed significantly increased serum HDL and tri-
glyceride levels compared with WT mice.
Diet-induced obesity is a well-known model of hyper-
leptinemia and central leptin resistance [43, 44]. In ro-
dents, high-fat intake may be associated with increased
serum leptin and obesity, and these leptin levels are
related to the body lipid content. In the present study,
EMD mice showed no changes in serum leptin concen-
trations after HFD. As EMD mice showed lower fat gain
with HFD and leptin is secreted in proportion to fat
stores [45], it is possible that EMD mice are more effi-
cient maintaining leptin sensitivity compared to wt mice
throughout the course of the HFD administration period
even to show leptin levels reduction.
Diet-induced obesity also predisposes individuals to
insulin resistance [46]. Elevations in circulating insulin
were evident in both mouse models of obesity used in
our study: genetic (EMD mice) and diet-induced obesity
model (HFD-fed wt mice). The present findings are im-
portant because hyperinsulinemia is a risk factor for
many, if not all, symptoms used to sort out the meta-
bolic syndrome and elevated insulin levels have been
suggested to be a causal factor for obesity [47, 48].
An increase in liver fat content has been shown to pre-
dict insulin resistance. It is generally thought that hep-
atic steatosis is developed via peripheral mechanisms
associated with obesity [49]. However, in our present
study, we show that EMD mice did not exhibit liver stea-
tosis. Some evidences indicate that experimental exercise
can prevent steatosis in HFD-induced obesity [50, 51].
Here we report increased anxiety behavior in NCD-fed
EMD mice. This was demonstrated in experiments car-
ried out using the elevated plus maze. EMD showed in-
creased number of entries and time spent in the open-
arms. These results indicated that EMD mice are more
prone to physical activity. This finding connecting in-
creased anxiety in EMD mice and greater physical activ-
ity may likely contribute to attenuate their liver steatosis.
Mitochondrial bioenergetics may be influenced by in-
sulin signaling [52]. At least in some tissues, impaired
mitochondrial function causes insulin resistance [53].
Our previous work showed endothelial BBB megalin de-
letion was associated with deficient mitochondrial com-
plex I in the brain cortex but increased mitochondrial
mass [10]. Then, we proposed that such mitochondrial
mass increase in EMD mice could be a consequence of
higher mitochondrial biogenesis. Indeed, here, we veri-
fied PGC-1α levels were increased in frontal cerebral
cortex from EMD mice. PGC-1α is expressed in the
brain, including the cerebral cortex, and hippocampus
[54, 55] and this protein is the master regulator for
mitochondrial biogenesis. Therefore, cells may compen-
sate for the energetic deficit due to reduced complex I
levels by increasing the mitochondrial biogenesis. HFD
administration increased the PGC-1α levels in wt mice
and therefore the mitochondrial biogenesis was found
upregulated. However, HFD did not affect the mitochon-
drial biogenesis already increased in EMD mice. Al-
though this is controversial, several previous works
demonstrated similar features showing increased
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mitochondrial content in skeletal muscle after HFD ad-
ministration [28, 56, 57] suggesting such increase in the
mitochondrial content could be beneficial for improving
insulin resistance at the beginning of HFD [58]. In
addition, we also found increased UCP2 levels in EMD
mice compared to wt animals, and HFD induced an in-
crease of these protein levels in wt mice but did not
affect the already increased levels in EMD mice. PGC-1α
regulates UCP2 protein expression and this protein plays
an important role in the regulation of energy metabolism
restoring glucose intolerance and insulin resistance [59,
60]. Regarding glucose metabolism, PGC-1α has been
associated with glucose intolerance and insulin resist-
ance as has been demonstrated using PGC-1α knockout
mice [61]. For example, loss of function or lower expres-
sion levels of PGC-1α has been associated with increased
risk of type 2 diabetes [62]. As suggested by Summer-
matter et al., PGC-1α could be involved in glucose re-
fueling and body lactate homeostasis [63]. Mitochondrial
uncoupling proteins as UCP2 could also regulate glucose
homeostasis and lipid metabolism [64]. UCPs increases
their neuronal expression induced by metabolic changes
and several works link UCP2 levels in the brain and sys-
temic metabolic abnormalities. For example, UCP2 was
found to increase in cerebral cortex mitochondria after
exercise [65]. UCP2 is involved in central autonomic,
endocrine, and metabolic regulation and is thus associ-
ated with cognition, mood, and behavior [66, 67]. UCP2
in the ventromedial nucleus restores glucose tolerance
and regulates insulin sensitivity mediated by glucose-
excited neurons, which is important for the physiological
control of systemic glucose metabolism [68]. We may
propose that metabolic changes in EMD mice induce el-
evated PGC-1α and UCP2 brain cortical expression and
we may hypothesize such elevated expression could be
considered a potential prevention mechanism against
HFD challenge trying to compensate defective mito-
chondria. This potential prevention mechanism may be
extensible against the brain inflammation pathways as
EMD mice exposed to HFD did not show evidence of in-
creased glial activation compared with mice from the
same group exposed to NCD. This protective effect
might be the result of higher energy expenditure, based
on the levels of the thermogenic factor PGC-1α that
were found significantly increased in the brain cortex
from EMD mice compared to wt.
Conclusion
In summary, EMD mice recapitulate several features
found in human dementia as AD, suggesting megalin as
a control gate for metabolic homeostasis. We may con-
clude that the metabolic phenotype of HFD-fed EMD
mice may be, at least in part, explained by improved glu-
cose tolerance.
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